GLP-1 challenger claims weight loss while maintaining muscle

New medical food claims to reduce weight and maintain muscle mass, unlike GLP-1s

(Image: Getty Images)

A new medical weight loss food has been approved for use in the US, with EU use eyed nextSigrid Therapeutics, a Stockholm, Sweden, based non-pharmaceutical health tech company has secured approval for its weight loss food technology SiPore, Carb Fence in the US, with Europe approval in progress.

Drugs like Ozempic have a positive impact on weight loss, though only for a short period, with long-term health implications of a growing concern, the business said.

GLP-1 drugs can also erode muscle mass by up to 40% as part of the weight loss process.

How do GLP-1s affect muscle mass?“Many individuals who discontinue GLP-1 drugs experience rapid weight regain, often without recovering lost muscle mass, which can make future weight loss even more challenging,” read a statement from Sigrid

Following the business’s SHINE study, the largest prediabetes study of its kind with 318 participants, it claims Carb Fence can preserve muscle mass at the same time as maintaining muscle loss.

Also read → Everything you need to know about GLP-1sThe study, conducted across 27 clinics in three European countries, demonstrated Carb Fence, which is a medical-grade liquid formula, can reduce blood sugar levels HbA1c (A1C), improves glucose metabolism and reduces body weight.

“These robust findings position Carb Fence as a pioneering medical food in the US, a category recognised by the US Food and Drug Administration for the dietary management of diseases or conditions under physician supervision,” said Sigrid co-founder and CEO Sana Alajmovic.

Medical foods in the US are experiencing significant growth, though Sigrid is also in discussions to secure CE-mark approval as a class IIb medical device in Europe, unlocking unmatched medical claims in the European market.

GLP-1 drug alternatives“The SHINE study validates SiPore as an innovative approach to metabolic health, supporting blood sugar regulation, weight management, and cardiovascular health,” said Kirsi Pietiläinen, Gyllenberg Professor in Clinical Metabolism at the Obesity Research Unit, University of Helsinki, and principal investigator for the SHINE study.

“The findings confirm that it preserves muscle mass while promoting fat loss, which is a significant advantage in tackling obesity and diabetes.”

Sigrid’s US approval and pending EU approval comes as recent analysis from the Global Burden of Diseases Study made revealed worrying data about the state of global consumers’ waistlines.

Some 60% of adults will be overweight or obese by 2050, with rates jumping up significantly within the last decade, according to the study.